EGFR
EGFR(表皮生长因子受体)
EGFR (epidermal growth factor receptor) is the cell-surface receptor of its specific ligands, including epidermal growth factor and TGFα (transforming growth factor α) and is a receptor tyrosine kinase.
EGFR 相关产品(242)
- GC47303Erlotinib-d6 (hydrochloride)CAS: 1189953-78-3纯度: >99.00%
An internal standard for the quantification of erlotinib
- GC50706JBJ-03-142-02CAS: 2068806-31-3纯度: >98.00%
Highly potent epidermal growth factor receptor (EGFR) and ErbB2 (human epidermal growth factor receptor; HER2) inhibitor
- GC60567Afatinib impurity 11CAS: 1402086-20-7纯度: >99.00%
Afatinib impurity 11 is an impurity of afatinib, an EGFR family inhibitor.
- GC60868Gefitinib D8CAS: 857091-32-8纯度: >98.00%
GefitinibD8(ZD1839D8)是Gefitinib的氘代物。Gefitinib是一种有效的(EGFR)抑制剂，在NR6wtEGFR细胞中IC50值为2-37nM。
- GC61161Osimertinib D6纯度: >99.50%
OsimertinibD6(AZD-9291D6)是Osimertinib的一种氘代化合物。Osimertinib是一种不可逆和突变的选择性的EGFR抑制剂，抑制EGFRL858R和EGFRL858R/T790M的IC50分别为12和1nM。
- GC61473Trastuzumab deruxtecanCAS: 1826843-81-5纯度: >98.50% / >99.00%
Trastuzumab deruxtecan（曲妥珠单抗）是一种人表皮生长因子受体2（HER2）靶向抗体-药物偶联物（ADC），由人源化抗人HER2（抗hHER2）抗体、酶促裂解肽接头和拓扑异构酶I抑制剂（DX-8951衍生物）组成。
- GC61490Trastuzumab emtansineCAS: 1018448-65-1纯度: >98.00%
Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa.
- GC61807(E/Z)-AG490CAS: 134036-52-5纯度: >98.00%
(E/Z)-AG490((E/Z)-TyrphostinAG490)是(E)-AG490和(Z)-AG490的消旋体。(E)-AG490是一种酪氨酸激酶抑制剂，可抑制EGFR，Stat-3和JAK2/3。
- GC62160Mobocertinib succinateCAS: 2389149-74-8纯度: >99.50%
An inhibitor of mutant EGFR and HER2 receptors
- GC62341RezivertinibCAS: 1835667-12-3纯度: >99.50%
Rezivertinib (BPI-7711) 是一种口服有效，高选择性和不可逆的第三代 EGFR 酪氨酸激酶抑制剂 (TKI)。Rezivertinib 对常见的激活 EGFR 和抗性T790M 突变具有高效力。Rezivertinib 具有出色的透过中枢神经系统 (CNS) 能力，并具有抗肿瘤活性。
- GC62384Epitinib succinateCAS: 2252334-12-4纯度: >99.00%
Epitinib succinate 是一种具有口服活性和选择性的表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKI)，可以透过血脑屏障。Epitinib succinate 可用于癌症研究。
- GC62481AST5902 trimesylate纯度: >99.50%
AST5902 is the principal metabolite of alflutinib both in vitro and in vivo, which exerts remarkable antineoplastic activity similar to alflutinib. AST5902 exhibits much weak CYP3A4 induction potential compared to alflutinib.
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC44263 | Myrtillin | 6906-38-3 | >99.50% / >98.00% | |
桃金娘苷（Delphinidin 3-o-glucoside）是一种花青素单体，主要分布于各种植物中，可用高效液相色谱法（HPLC）质谱法（Mass）和核磁共振法进行定性和定量分析(NMR)。 | ||||
| GC44491 | O-Desmethyl Gefitinib | 847949-49-9 | >98.00% | |
A major active metabolite of gefitinib | ||||
| GC44583 | PD 089828 | 179343-17-0 | >98.00% | |
An inhibitor of EGFR, PDGFβ, FGF, and c-Src | ||||
| GC47303 | Erlotinib-d6 (hydrochloride) | 1189953-78-3 | >99.00% | |
An internal standard for the quantification of erlotinib | ||||
| GC50013 | AG 1478 hydrochloride | 170449-18-0 | - | |
An inhibitor of EGF receptor kinase | ||||
| GC50026 | BIBX 1382 dihydrochloride | 1216920-18-1 | - | |
An EGFR inhibitor | ||||
| GC50083 | PKI 166 hydrochloride | 2230253-82-2 | - | |
An inhibitor of EGFR | ||||
| GC50706 | JBJ-03-142-02 | 2068806-31-3 | >98.00% | |
Highly potent epidermal growth factor receptor (EGFR) and ErbB2 (human epidermal growth factor receptor; HER2) inhibitor | ||||
| GC60154 | Erlotinib D6 | 1034651-23-4 | - | |
An internal standard for the quantification of erlotinib | ||||
| GC60567 | Afatinib impurity 11 | 1402086-20-7 | >99.00% | |
Afatinib impurity 11 is an impurity of afatinib, an EGFR family inhibitor. | ||||
| GC60868 | Gefitinib D8 | 857091-32-8 | >98.00% | |
GefitinibD8(ZD1839D8)是Gefitinib的氘代物。Gefitinib是一种有效的(EGFR)抑制剂，在NR6wtEGFR细胞中IC50值为2-37nM。 | ||||
| GC61161 | Osimertinib D6 | - | >99.50% | |
OsimertinibD6(AZD-9291D6)是Osimertinib的一种氘代化合物。Osimertinib是一种不可逆和突变的选择性的EGFR抑制剂，抑制EGFRL858R和EGFRL858R/T790M的IC50分别为12和1nM。 | ||||
| GC61473 | Trastuzumab deruxtecan | 1826843-81-5 | >98.50% / >99.00% | |
Trastuzumab deruxtecan（曲妥珠单抗）是一种人表皮生长因子受体2（HER2）靶向抗体-药物偶联物（ADC），由人源化抗人HER2（抗hHER2）抗体、酶促裂解肽接头和拓扑异构酶I抑制剂（DX-8951衍生物）组成。 | ||||
| GC61490 | Trastuzumab emtansine | 1018448-65-1 | >98.00% | |
Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa. | ||||
| GC61780 | SU5204 | 186611-11-0 | >98.50% | |
SU5204 is a tyrosine kinase inhibitor with IC50 of 4 μM and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively. | ||||
| GC61807 | (E/Z)-AG490 | 134036-52-5 | >98.00% | |
(E/Z)-AG490((E/Z)-TyrphostinAG490)是(E)-AG490和(Z)-AG490的消旋体。(E)-AG490是一种酪氨酸激酶抑制剂，可抑制EGFR，Stat-3和JAK2/3。 | ||||
| GC62159 | Tucatinib hemiethanolate | 1429755-56-5 | >99.00% | |
An inhibitor of HER2 | ||||
| GC62160 | Mobocertinib succinate | 2389149-74-8 | >99.50% | |
An inhibitor of mutant EGFR and HER2 receptors | ||||
| GC62341 | Rezivertinib | 1835667-12-3 | >99.50% | |
Rezivertinib (BPI-7711) 是一种口服有效，高选择性和不可逆的第三代 EGFR 酪氨酸激酶抑制剂 (TKI)。Rezivertinib 对常见的激活 EGFR 和抗性T790M 突变具有高效力。Rezivertinib 具有出色的透过中枢神经系统 (CNS) 能力，并具有抗肿瘤活性。 | ||||
| GC62384 | Epitinib succinate | 2252334-12-4 | >99.00% | |
Epitinib succinate 是一种具有口服活性和选择性的表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKI)，可以透过血脑屏障。Epitinib succinate 可用于癌症研究。 | ||||
| GC62385 | Simotinib | 944258-89-3 | >99.00% | |
Simotinib 是一种选择性、特异性、口服生物利用度高的 EGFR 酪氨酸激酶抑制剂，IC50 为 19.9 nM。抗肿瘤活性。 | ||||
| GC62402 | ASK120067 | 1934259-00-3 | >98.00% | |
ASK120067 (ASK120067) 是一种有效的口服活性 EGFRT790M (IC50:0.3 nM) 抑制剂，选择性高于 EGFRWT (IC50:6.0 nM)。 ASK120067是用于非小细胞肺癌（NSCLC）研究的第三代EGFR-TKI。 | ||||
| GC62420 | EMI56 | 2414374-41-5 | >99.50% | |
EMI56 是 EMI1 的衍生物，EMI56 比 EMI1 对突变型 EGFR 具有更大的效力。EMI56 抑制 EGFR 三重突变体。 | ||||
| GC62481 | AST5902 trimesylate | - | >99.50% | |
AST5902 is the principal metabolite of alflutinib both in vitro and in vivo, which exerts remarkable antineoplastic activity similar to alflutinib. AST5902 exhibits much weak CYP3A4 induction potential compared to alflutinib. | ||||